May 1, 2006Diabetes124 citationsOpen Access
Adiponectin Genetic Variability, Plasma Adiponectin, and Cardiovascular Risk in Patients With Type 2 Diabetes
Key Result
In diabetic patients, ADIPOQ polymorphism -11365C-->G was associated with lower plasma adiponectin, while -4034C homozygotes had a 60% increased cardiovascular risk (OR 1.62; 95% CI 1.07-2.45).
Study Design
Type
Case-Control (n=989)
Structured PICO
Do ADIPOQ gene variants affect circulating adiponectin levels and cardiovascular risk in patients with type 2 diabetes?
P
Population
989 women with type 2 diabetes from the Nurses' Health Study (285 developed CVD, 704 controls), plus a meta-analysis cohort of 827 CVD cases and 1,887 CVD-free controls with diabetes.
I
Intervention
ADIPOQ gene polymorphisms (including -11365C-->G, -4034A-->C, and +276G-->T)
C
Comparator
Reference alleles or most common haplotypes (e.g., CAATG)
O
Outcome
Cardiovascular disease (CVD) risk and circulating plasma adiponectin levelshard clinical
Specific ADIPOQ gene polymorphisms are significantly associated with altered plasma adiponectin levels and cardiovascular risk in women with type 2 diabetes.
Main Result
Effect estimate: OR 1.62 (95% CI 1.07-2.45)
Abstract
Adiponectin is an adipocyte-derived hormone that has shown anti-inflammatory and antiatherogenic effects. We assessed the associations of variants in the adiponectin gene (ADIPOQ) with circulating adiponectin levels and cardiovascular risk among women with type 2 diabetes. Of 989 diabetic women from the Nurses' Health Study, 285 developed cardiovascular disease (CVD) during follow-up through 2000. We genotyped five ADIPOQ polymorphisms in the CVD case and control subjects. A promoter polymorphism -11365C-->G was significantly associated with lower plasma adiponectin levels (P = 0.004). The homozygotes of allele -4034C were significantly associated with approximately 60% increased cardiovascular risk (odds ratio 1.62 95% CI 1.07-2.45). Adjustment for age, BMI, and other covariates did not appreciably change the associations. In addition, a common haplotype possessing allele +276T (CAATT) was associated with a significantly lower CVD risk than the most common haplotype (CAATG) (0.70 0.50-0.98). In our meta-analysis of 827 CVD case and 1,887 CVD-free control subjects, polymorphism +276G-->T was significantly associated with approximately 45% (20-62%) decreased CVD risk under a recessive inheritance mode in diabetic patients. In conclusion, ADIPOQ promoter polymorphism -11365C-->G was associated with plasma adiponectin levels, whereas polymorphisms -4034A-->C and +276G-->T were associated with CVD risk in diabetic patients.